We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

761 hedge funds and large institutions have $9.17B invested in State Street SPDR S&P Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 77 funds opening new positions, 253 increasing their positions, 254 reducing their positions, and 101 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less repeat investments, than reductions

Existing positions increased: 253 | Existing positions reduced: 254

2% less funds holding

Funds holding: 780 → 761 (-19)

4.49% less ownership

Funds ownership: 126.4% → 121.91% (-4.5%)

22% less funds holding in top 10

Funds holding in top 10: 23 → 18 (-5)

24% less first-time investments, than exits

New positions opened: 77 | Existing positions closed: 101

24% less capital inflows, than outflows

Capital inflows: $1.28B | Capital outflows: $1.68B

46% less call options, than puts

Call options by funds: $1.6B | Put options by funds: $2.95B

Holders
761
Holders Change
-19
Holders Change %
-2.44%
% of All Funds
10.96%
Holding in Top 10
18
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-21.74%
% of All Funds
0.26%
New
77
Increased
253
Reduced
254
Closed
101
Calls
$1.6​B
Puts
$2.95​B
Net Calls
-⁠$1.35​B
Net Calls Change
+$368​M

XBI Hedge Fund Activity: Q2 2024 in Review

761 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2024, worth a combined $9.17B — down 5.7% from $9.7B a quarter earlier.

Sellers outnumbered buyers: 101 funds closed out of XBI and 77 opened new positions — a net loss of 24 holders — while 254 trimmed existing stakes and 253 added.

The largest buyer was JP Morgan Chase, adding an estimated $402M. The largest seller was Citadel Advisors, cutting an estimated $167M.

  • 761 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2024, down from 780 in Q1 2024.
  • Funds reported $9.17B of State Street SPDR S&P Biotech ETF stock for Q2 2024, down 5.7% quarter-over-quarter.
  • 77 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2024 and 101 closed out, a net change of -24 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q2 2024 was JP Morgan Chase, an estimated $402M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q2 2024 was Citadel Advisors, an estimated $167M sold.

Based on aggregated 13F filings for Q2 2024.